Defining a molecular phenotype for benign and malignant parathyroid tumors
Authors:
- Mariwil WongMWMariwil Wong
- Orlo H. ClarkOCOrlo H. Clark
Open Access
Abstract
BACKGROUND: It is frequently difficult to establish histologically whether a parathyroid tumor is a parathyroid carcinoma, parathyromatosis, or an atypical adenoma. The authors asked whether these tumors have a distinctive molecular profile, whether benign tumors could be distinguished from malignant tumors, and whether parathyromatosis is a low‐grade parathyroid carcinoma or is benign tissue that can invade other organs.METHODS: Samples of parathyroid carcinoma, atypical adenoma, parathyromatosis, parathyroid adenoma, and hyperplasia were obtained for tissue microarray studies. The molecular expression of genes involved in parathyroid tumor progression (HRPT2 [“parafibromin”], galectin‐3, Ki‐67, Rb, p27, and mdm‐2) was investigated by immunohistochemistry.RESULTS: Complete loss of parafibromin expression was seen in 5 of 16 (31.3%) parathyroid carcinomas; all parathyromatosis, atypical adenomas, adenomas, and hyperplasia stained positive for parafibromin. Loss of Rb expression was seen in 5 (33.3%) of 15 parathyroid carcinomas and 1 (7.1%) of 14 parathyroid hyperplasias; all parathyromatosis, atypical adenomas, and adenomas stained positive. Galectin‐3 stained strongly positive in 14 (93.3%) of 15 parathyroid carcinomas, and positive in 3 (18.7%) of 16 cases of parathyromatosis, 2 (100%) of 2 atypical adenomas, 1 (5.6%) of 18 adenomas, and 2 (14.3%) of 14 hyperplasias. The Ki‐67 proliferative index was high in 9 (60%) of 15 parathyroid carcinomas, 1 (6.7%) of 15 cases of parathyromatosis, 1 (5.6%) of 18 adenomas, and no atypical adenomas or hyperplasia. P27 and mdm‐2 protein expression did not differ appreciably among the tumor types.CONCLUSIONS: No single diagnostic marker currently determines whether a parathyroid tumor is a parathyroid carcinoma, but loss of parafibromin and Rb expression, and overexpression of galectin‐3, generally distinguish parathyroid carcinoma from other parathyroid tumors. Parathyromatosis does not appear to be a low‐grade parathyroid carcinoma. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 34 references indexed in Scilit:
- Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?Cancer, 2007
- Is galectin‐3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of “follicular neoplasm”? A critical appraisal of the evidenceHead & Neck, 2007
- Galectin-3 and Ki-67 Expression in Multiglandular Parathyroid LesionsAmerican Journal of Clinical Pathology, 2006
- Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent mannerBiochemical and Biophysical Research Communications, 2006
- On the role of galectin-3 in cancer apoptosisApoptosis, 2005
- HRPT2 mutations are associated with malignancy in sporadic parathyroid tumoursJournal of Medical Genetics, 2003
- HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndromeNature Genetics, 2002
- Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors?The Journal of Clinical Endocrinology & Metabolism, 1996
- Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumoursClinical Endocrinology, 1996
- p53 abnormalities in human parathyroid carcinomaThe Journal of Clinical Endocrinology & Metabolism, 1994